Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Down 63.1% in December

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) was the recipient of a significant decline in short interest in December. As of December 15th, there was short interest totalling 83,700 shares, a decline of 63.1% from the November 30th total of 226,700 shares. Based on an average trading volume of 449,700 shares, the short-interest ratio is currently 0.2 days. Currently, 0.5% of the company’s shares are sold short.

Sensei Biotherapeutics Stock Up 3.5 %

NASDAQ:SNSE traded up $0.02 during midday trading on Friday, hitting $0.50. The stock had a trading volume of 102,452 shares, compared to its average volume of 206,709. The stock has a 50-day moving average of $0.51 and a 200 day moving average of $0.57. The company has a market capitalization of $12.47 million, a price-to-earnings ratio of -0.42 and a beta of 0.16. Sensei Biotherapeutics has a one year low of $0.38 and a one year high of $1.94.

Hedge Funds Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. National Bank of Canada FI boosted its holdings in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,575 shares of the company’s stock after acquiring an additional 35,575 shares during the period. National Bank of Canada FI owned about 0.18% of Sensei Biotherapeutics worth $27,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 10.50% of the stock is currently owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.